down arrow

Processa Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74275C2052
USD
0.27
0.01 (3.51%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.260.29

52 Week

0.151.50
Valuation
Technical
Day's Volume

CASH

1.56 M

Shareholding (Mar 2025)

FII

0.00%

Held by 2 FIIs

DII

98.69%

Held by 1 DIIs

Promoter

0.00%

How big is Processa Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Processa Pharmaceuticals, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million, with a net profit of -11.95 million over the last four quarters. The balance sheet shows shareholder's funds of 1.70 million and total assets of 3.23 million.

As of Jun 18, Processa Pharmaceuticals, Inc. has a market capitalization of 3.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a consolidated net profit of -11.95 million during the same period.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 1.70 million and total assets amounting to 3.23 million.

Read More

What does Processa Pharmaceuticals, Inc. do?

22-Jun-2025

Processa Pharmaceuticals, Inc. is a micro-cap pharmaceutical company focused on developing drug products to improve survival and quality of life for patients with unmet medical needs. As of March 2025, it reported a net profit loss of $3 million and has a market cap of $3.09 million.

Overview: <BR>Processa Pharmaceuticals, Inc. is a pharmaceutical company focused on developing drug products aimed at improving the survival and quality of life for patients with unmet medical needs, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 3.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.81 <BR>Return on Equity: -339.08% <BR>Price to Book: 0.88<BR><BR>Contact Details: <BR>Address: 7380 Coca Cola Dr Ste 106, HANOVER MD: 21076-1789 <BR>Tel: 1 443 7763133 <BR>Fax: 1 443 2884420

Read More

Who are in the management team of Processa Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Processa Pharmaceuticals, Inc. includes Dr. David Young as Chairman, CEO, and Founder, along with Directors Dr. Khalid Islam, Ms. Geraldine Pannu, Mr. Virgil Thompson, and Mr. Justin Yorke.

As of March 2022, the management team of Processa Pharmaceuticals, Inc. includes Dr. David Young, who serves as the Chairman of the Board, Chief Executive Officer, and Founder. Other members of the Board of Directors are Dr. Khalid Islam, Ms. Geraldine Pannu, Mr. Virgil Thompson, and Mr. Justin Yorke, all of whom hold the designation of Director.

Read More

Is Processa Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of June 23, 2025, Processa Pharmaceuticals, Inc. is in a mildly bearish trend, with daily indicators suggesting bearishness despite some bullish signals on longer timeframes, and it has underperformed the S&P 500 with a year-to-date return of -76.53%.

As of 23 June 2025, the technical trend for Processa Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages and Dow Theory both indicating bearishness. Weekly and monthly MACD readings are mildly bullish, but the overall trend remains negative. The RSI shows a bullish signal on the monthly timeframe, while Bollinger Bands indicate a mildly bearish stance. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -76.53% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.13

stock-summary
Return on Equity

-210.93%

stock-summary
Price to Book

1.50

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
44.49%
0%
44.49%
6 Months
-5.93%
0%
-5.93%
1 Year
-74.65%
0%
-74.65%
2 Years
-98.22%
0%
-98.22%
3 Years
-85.69%
0%
-85.69%
4 Years
-99.72%
0%
-99.72%
5 Years
-99.82%
0%
-99.82%

Processa Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Processa Pharmaceuticals, Inc. technically bullish or bearish?

As of 23 June 2025, the technical trend for Processa Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages and Dow Theory both indicating bearishness. Weekly and monthly MACD readings are mildly bullish, but the overall trend remains negative. The RSI shows a bullish signal on the monthly timeframe, while Bollinger Bands indicate a mildly bearish stance. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -76.53% compared to the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-208.49%
EBIT to Interest (avg)
-14.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.81
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.24%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.01
EV to EBIT
-0.06
EV to EBITDA
-0.06
EV to Capital Employed
0.73
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1208.86%
ROE (Latest)
-339.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.31%)

Foreign Institutions

Held by 2 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -30.00% vs -15.38% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-3.10",
          "chgp": "-29.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.90",
          "val2": "-3.00",
          "chgp": "-30.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -7.21% vs 59.49% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.10",
          "val2": "-11.50",
          "chgp": "-5.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-11.10",
          "chgp": "-7.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-3.10
-29.03%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.90
-3.00
-30.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -30.00% vs -15.38% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.10
-11.50
-5.22%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.90
-11.10
-7.21%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -7.21% vs 59.49% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Processa Pharmaceuticals, Inc. stock-summary
stock-summary
Processa Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Processa Pharmaceuticals, Inc., formerly Heatwurx, Inc., is a pharmaceutical company. The Company is focused on the development of drug products that are intended to improve the survival and/or quality of life for patients who have unmet medical need. The Company’s product portfolio includes 499. It is developing 499 for the treatment of Necrobiosis Lipoidica. It is also developing 499 for the treatment of effects related to head and neck cancer.
Company Coordinates stock-summary
Company Details
7380 Coca Cola Dr Ste 106 , HANOVER MD : 21076-1789
stock-summary
Tel: 1 443 7763133
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."